Today
Breathing room: Healthscope lenders in standstill vote
Instead of preparing Healthscope for a float, Brookfield has been forced to inject emergency funding into the company.
Yesterday
Ramsay says Labor’s premium hike will not cover soaring hospital costs
Still, shares in the country’s largest private hospital operator rose sharply after it appointed Goldman Sachs to assess the sale of its European business.
This Month
Telix Pharma CEO in $120m block trade; taps JPMorgan
Telix boss Christian Behrenbruch and the other seller had agreed to a 12-month escrow.
Big pharma sues GenesisCare over Labor-endorsed copycat cancer drug
Swiss pharma giant Novartis is taking legal action against the Australian cancer care provider as a dispute over how to fund and regulate nuclear medicines escalates.
Why a Mediscare campaign won’t be so easy this time around
Labor’s Medicare package offers politically popular relief for GP visits but may not convince voters losing confidence in Australia’s public health system.
Genesis Capital gets back into general practice with Ochre Health
Genesis has partnered with doctor Hamish Meldrum who will keep a significant shareholding in the business.
My patient Shirley would benefit from more bulk billing. Here’s why she won’t
Labor is shining an 8.5 billion-watt spotlight on general practices to divert attention from the elephant in the room that everyone in Australia has seen.
Doctors say not all GP visits will be free under Labor plan
Medical professionals welcome the $8.5 billion Medicare overhaul but urge targeted funding to care for patients who need it most.
Albanese makes $8.5b Medicare overhaul his signature election policy
The prime minister will make Medicare the centrepiece of his re-election campaign, promising to spend big to eliminate patient costs for visits to the doctor.
Star biotech Telix makes $1.2b revenue pledge
The Melbourne-based nuclear medicine company is expected to be a major player in the US radiopharmaceutical market.
US pharma giant Cosette makes $672m bid for Mayne Pharma
US pharma giant Cosette has offered $7.40 a share for Mayne Pharmaceuticals, a premium to recent trading but a fraction of the $42 it was trading at in 2016.
Ramsay’s global CFO search for a hospital pass job
Does the healthcare outfit really think someone will move to Australia to manage the colossal mess that is our private hospital market?
Healthscope to close maternity wards in Darwin and Hobart
The Coalition has seized on the shutdowns to accuse Labor of failing to take action to stop the closure of critical health service
David Di Pilla thinks a new PE owner could save Healthscope
Property is at the heart of the veteran deal maker’s plans for the private hospitals operator – just as it was at Masters almost a decade ago.
TGA approves weight-loss drug to treat heart disease
Regulators say the weight-loss drug Wegovy can now be used to treat more than 3 million overweight Australians with heart disease.
Catholic Health’s new plan to fix hospitals at ‘breaking point’
Private hospital groups have sent Labor a package of proposals they say can save the struggling sector.
David Di Pilla’s HMC Capital eyes Healthscope hospitals
The alternative asset manager and other operators are talking to Healthscope’s landlords about taking over Australia’s second-biggest hospital group.
Cochlear says US cost-of-living pressures hit services revenue
Cochlear expects full-year earnings to come in at the lower end of guidance, despite rising sales of its implants.
Chemist Warehouse scores $34b pay day in ASX debut
The founders were on hand as the retailer made its sharemarket debut on Thursday via Sigma, with plans to expand in Australia and globally.
Is Ramsay Health Care whipping itself into a frenzy?
The private hospital lobby is turning on itself and Labor is making mileage from it.